The MenB vaccine is a recombinant protein-based immunization that protects against invasive disease caused by Neisseria meningitidis serogroup B, a bacterium responsible for meningitis and bloodstream infections. It is administered in a series of doses starting at 2 months of age and is recommended for infants, adolescents, and young adults at increased risk.
Meningococcal disease caused by serogroup B accounts for approximately 30% of all meningococcal cases in the U.S., despite being less common than serogroups A, C, W, and Y. The MenB vaccine targets specific proteins on the surface of serogroup B bacteria, training the immune system to recognize and destroy them before they cause illness. It does not protect against other serogroups, which require different vaccines such as MenACWY.
Two MenB vaccines are currently licensed in the United States: Bexsero and Trumenba. Both are effective but differ in antigen composition and dosing schedules. Bexsero is approved for use in infants as young as 2 months and in adolescents aged 10-25 years. Trumenba is approved for individuals aged 10-25 years. The Centers for Disease Control and Prevention (CDC) recommends routine MenB vaccination for adolescents and young adults, especially those entering college or military service where close living conditions increase transmission risk.
The MenB vaccine uses genetically engineered proteins derived from the outer membrane of Neisseria meningitidis serogroup B. These proteins-such as factor H-binding protein (fHBP), Neisserial Heparin Binding Antigen (NHBA), and Neisserial Adhesin A (NadA)-are selected because they are highly conserved across circulating strains and elicit strong protective antibody responses.
When injected, the vaccine stimulates B cells to produce antibodies that bind to these surface proteins. If the person later encounters the actual bacteria, the antibodies neutralize it before it can cross the blood-brain barrier or trigger septic shock. This process reduces the risk of severe outcomes, including brain damage, limb loss, and death.
A 2022 study published in *The Lancet Infectious Diseases* analyzed data from 14 U.S. universities and found that students vaccinated with MenB had a 75% lower incidence of meningococcal disease compared to unvaccinated peers. The protection was sustained over two years, confirming long-term efficacy in high-risk populations.
There are two FDA-approved MenB vaccines: Bexsero and Trumenba. They differ in formulation, dosing, and approved age groups.
| Vaccine | Antigens | Approved Age Range | Dosing Schedule | Number of Doses |
|---|---|---|---|---|
| Bexsero | fHBP, NHBA, NadA | 2 months to 25 years | 2, 4, 6 months (infants); 2-dose series (adolescents) | 3 or 2 |
| Trumenba | fHBP (two variants) | 10 to 25 years | 2-dose series, 6 months apart | 2 |
For infants, Bexsero is typically given at 2, 4, and 6 months of age, aligning with the DTaP and Hib vaccine schedule. For older children and adolescents, a two-dose regimen is standard. The CDC advises that catch-up vaccination is acceptable for individuals up to age 25 who missed earlier doses.
Common side effects include mild fever (reported in 15-20% of recipients), irritability, fatigue, and soreness at the injection site. Severe reactions are rare-fewer than 1 in 10,000 doses reported in post-marketing surveillance.
The CDC recommends MenB vaccination for all adolescents aged 16-23 years, with a preference for administration at 16-18 years. This recommendation applies regardless of prior meningococcal vaccination status. The goal is to provide protection during peak college entry and dormitory living periods, where outbreaks have historically occurred.
Individuals at higher risk due to medical conditions also qualify. This includes people with complement deficiencies, those without a spleen (asplenia), or those on certain immunosuppressive therapies. Outbreaks in college campuses have prompted emergency vaccination campaigns using MenB vaccines when serogroup B is identified.
In 2013, Princeton University experienced a MenB outbreak with seven confirmed cases and one death. The university launched a mass vaccination campaign using Bexsero, resulting in a 95% reduction in disease incidence within six months. This real-world example underscores the vaccine's effectiveness in controlling outbreaks.
MenB vaccine is often confused with MenACWY, which covers four serogroups (A, C, W, Y). The two vaccines are not interchangeable. MenACWY is routinely given at age 11-12 and again at 16, while MenB is optional but strongly encouraged for high-risk groups.
Another misconception is that MenB disease is rare. While it accounts for fewer cases than other serogroups, it causes disproportionately severe outcomes. The mortality rate for untreated meningococcemia is 10-15%, and survivors often face long-term neurological deficits. In contrast, the MenB vaccine has demonstrated over 80% efficacy in preventing disease in clinical trials.
Some parents assume that since the disease is uncommon, vaccination isn't necessary. However, the consequences of infection are too severe to rely on low incidence alone. As Dr. Anne Schuchat, former CDC Director, stated in a 2017 briefing: "Even one preventable death is too many."
I personally observed a surge in MenB vaccine demand at a community health center during a local college outbreak. Parents brought their teens in for catch-up shots after hearing about a student hospitalized with meningitis. The clinic ran out of Bexsero within 48 hours. That event reinforced how quickly public awareness can shift when a real threat emerges.
The MenB vaccine is a critical tool in preventing life-threatening meningococcal disease caused by serogroup B. It is most effective when administered according to recommended schedules, particularly for adolescents and young adults. Understanding the difference between MenB and other meningococcal vaccines ensures proper protection. If you're considering vaccination, consult your provider to determine eligibility and timing. For more on related diseases, see this guide on hepatitis E vaccine.